☆ 4.7 Review

Cardiovascular Complications of Prostate Cancer Treatment

FRONTIERS IN PHARMACOLOGY (2020)

Journal

FRONTIERS IN PHARMACOLOGY

Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA

DOI: 10.3389/fphar.2020.555475

Keywords

prostate cancer; treatment; cardiovascular; complications; cardio-oncology

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved. Currently, the systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Unfortunately, many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. Additionally, this article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study

Michal Wilk, Anna Wasko-Grabowska, Iwona Skoneczna, Sebastian Szmit

Summary: The presence of well-controlled hypertension, stable coronary artery disease, and the use of angiotensin system inhibitors (ASi) were associated with longer time to treatment failure (TTF) in post-chemotherapy mCRPC patients receiving ABI therapy. These factors may potentially serve as non-oncological predictive markers for prolonged ABI therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology

Zehua Liang, Yuquan He, Xin Hu

Summary: Chemotherapy-induced cardiovascular toxicity has become a major concern in cancer therapy. Traditional Chinese medicine formulations and the emerging field of reverse cardio-oncology provide promising approaches for prevention and treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Yinghui Wang, Yonggang Wang, Xiaorong Han, Jian Sun, Cheng Li, Binay Kumar Adhikari, Jin Zhang, Xiao Miao, Zhaoyang Chen

Summary: Cardiovascular disease (CVD) and cancer are leading causes of death worldwide. The adverse effects of anti-tumor therapy, particularly on the cardiovascular system, have gained significant attention. Incidence of cardiovascular events is higher than tumor recurrence rate, and CVD and malignant tumors share common risk factors. Clinicians should understand this relationship, provide primary and secondary prevention strategies, and follow proper treatment methods.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology

Shawn Simek, Brian Lue, Anjali Rao, Goutham Ravipati, Srilakshmi Vallabhaneni, Kathleen Zhang, Vlad G. Zaha, Alvin Chandra

Summary: Gender differences exist in the medical field, including cardio-oncology. Gender may influence cancer susceptibility, cardiotoxicities, healthcare, and cancer treatments.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Oncology

Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies

Jakub Bychowski, Wojciech Sobiczewski

Summary: Cancer and cardiac diseases are the leading causes of death in developed countries. Due to advancements in detection and treatment, more cancer patients are surviving and living longer. However, there is an increasing risk of cardiovascular complications from cancer therapies, such as heart dysfunction and premature heart disease. Cardio-oncology is a new field that focuses on screening, diagnosis, and prevention of these adverse effects. This review discusses the most relevant studies on cardiac effects of oncological therapy and methods for prevention.

CANCER MEDICINE (2023)

Add to Collection

Review Oncology

Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology

Mengjia Chen, Jianing Xue, Maoling Wang, Junyao Yang, Ting Chen

Summary: The potential coexistence of cardiovascular disease and cancer is more likely in long-term survivors due to advancements in cancer therapy. Cardiotoxicity is a well-known and concerning adverse effect of cancer treatments, which can lead to the discontinuation of life-saving anticancer treatments and negatively impact patient survival. Different anticancer treatments have varying effects on the cardiovascular system, and the incidence of cardiovascular events also varies among different tumor protocols. Comprehensive cardiovascular risk assessment and clinical monitoring should be considered for cancer treatments, with emphasis on baseline cardiovascular evaluation risk before initiating therapy. Additionally, cardio-oncology services are needed to identify and reduce cardiovascular side effects, as well as minimize long-term cardiotoxic effects.

CANCERS (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis

Graeme J. Koelwyn, Joseph Pierre Aboumsallem, Kathryn J. Moore, Rudolf A. de Boer

Summary: Recent studies have shown a complex relationship between cardiovascular disease (CVD) and cancer, where development of CVD before or after a cancer diagnosis can lead to increased risk of cancer and worsened outcomes for patients. This emerging concept of 'reverse-cardio-oncology' suggests that CVD can accelerate cancer pathogenesis.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2022)

Add to Collection

Article Oncology

Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic

Peter G. Doukas, Ruchi N. Patel, Vishnu Venkatesh, Sadiya S. Khan, Abigail Baldridge, Nausheen Akhter

Summary: The study aimed to optimize cardiac health of cancer patients in a cardio-oncology clinic. The research focused on breast cancer patients and found the importance of optimizing cardiovascular health in this patient population.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Pediatrics

Current State of Pediatric Cardio-Oncology: A Review

Molly Brickler, Alexander Raskin, Thomas D. Ryan

Summary: The landscape of pediatric oncology has changed significantly, with improved survival rates due to advancements in chemotherapy and development of novel therapies. However, many targeted treatments can lead to cardiovascular pathologies. Data on prevention and treatment strategies for pediatric cardiac diseases are lacking, leading to practice variability. Future research should focus on prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and understanding the role of genetic susceptibility. Collaboration between pediatric cardiologists and oncologists is crucial for better understanding and preventing cardiac diseases in pediatric oncology patients.

CHILDREN-BASEL (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardio-oncology imaging tools at the translational interface

Katarina Yaros, Benay Eksi, Alvin Chandra, Kartik Agusala, Lorenz H. Lehmann, Vlad G. Zaha

Summary: Cardiovascular imaging plays an important role in the care of cancer patients, as they face increased risks of cardiovascular complications. Currently established imaging modalities are evolving towards increased specificity, while new modalities are emerging to target earlier stages of cardiovascular disease. Choosing suitable imaging modalities for individual patients is crucial for successful risk stratification. Future imaging tools have the potential to provide insights into the molecular pathology of cardiovascular complications associated with cancer and oncological therapies.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Essentials of cardio-oncology

Vera Vaz Ferreira, Arjun K. Ghosh

Summary: Cardio-oncology is a subspecialty that provides cardiac care for cancer patients. Cardiovascular toxicity (CVT) caused by newer oncological agents has emerged as a concern, emphasizing the need for baseline assessment and individualized surveillance during and after cancer therapy. Early diagnosis and management strategies are crucial.

CLINICAL MEDICINE (2023)

Add to Collection

Review Endocrinology & Metabolism

Ketogenic Diets and Cardio-Metabolic Diseases

Weiyue Zhang, Xin Guo, Lulu Chen, Ting Chen, Jiayu Yu, Chaodong Wu, Juan Zheng

Summary: The ketogenic diet (KD) has shown promising effects in managing various cardio-metabolic diseases (CMDs) like obesity, heart failure, and hypertension, but remains controversial in diabetes and dyslipidemia. Current evidence suggests that KD is generally protective against obesity-related cardiovascular diseases (CVDs) but contradictory in diabetes and other metabolic disorder-related CVDs. More rigorous research focusing on clinical safety, treatment duration, and plan of KDs is needed to address the existing controversies.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Irma Bisceglia, Maria Laura Canale, Nicola Silvestris, Giuseppina Gallucci, Andrea Camerini, Alessandro Inno, Massimiliano Camilli, Fabio Maria Turazza, Giulia Russo, Andrea Paccone, Raffaella Mistrulli, Leonardo De Luca, Stefania Angela Di Fusco, Luigi Tarantini, Fabiana Luca, Stefano Oliva, Antonella Moreo, Nicola Maurea, Vincenzo Quagliariello, Giuseppina Rosaria Ricciardi, Chiara Lestuzzi, Damiana Fiscella, Iris Parrini, Vito Racanelli, Antonio Russo, Lorena Incorvaia, Fabio Calabro, Giuseppe Curigliano, Saverio Cinieri, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Furio Colivicchi

Summary: In cancer, patients are considered survivors throughout their entire journey from initial diagnosis to the end of life. The increase in the number of cancer survivors calls for attention to therapy-related cardiovascular toxicity. Personalized care and multidisciplinary collaboration are crucial for the healthcare of cancer survivors.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Add to Collection

Article Medicine, Research & Experimental

Disparities in cardio-oncology: Implication of angiogenesis, inflammation, and chemotherapy

Carlos D. Vera, Agustin Rodriguez Lopez, Alex S. Ewaneewane, Kasey Lewis, Sophia Parmisano, Gema Mondejar-Parreno, Chandan Upadhyaya, Mckay Mullen

Summary: Cancer and cardiovascular diseases are the top two causes of death in the United States. While novel therapies have slowed down cancer mortality rate, there has been an increase in cardiac failures due to the toxicity of cancer treatments. Understanding the mechanisms behind this relationship is crucial in properly treating patients at risk of developing cardiac failure. Currently, early-stage biomarkers of inflammation and angiogenesis are used to detect cardiotoxicity before it becomes irreversible, with the aim of minimizing the adverse effects of cancer therapies. In the field of cardio-oncology, there is growing focus on gender and racial disparities in cardiotoxicity and their impact on disease outcomes, although data on variations in cardiotoxicity across diverse populations is limited.

LIFE SCIENCES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients

Alessandra Cuomo, Valentina Mercurio, Gilda Varricchi, Maria Rosaria Galdiero, Francesca Wanda Rossi, Antonio Carannante, Grazia Arpino, Luigi Formisano, Roberto Bianco, Chiara Carlomagno, Carmine De Angelis, Mario Giuliano, Elide Matano, Marco Picardi, Domenico Salvatore, Ferdinando De Vita, Erika Martinelli, Carminia Maria Della Corte, Floriana Morgillo, Michele Orditura, Stefania Napolitano, Teresa Troiani, Carlo G. Tocchetti

Summary: A large Cardio-Oncology unit in Southern Italy has described the impact on 231 consecutive patients referred to their unit, categorizing patients into three types based on their chemotherapeutic statuses. Results showed that patients already being treated with oncological treatments (Type 2) had the highest incidence of cardiovascular events, withdrawals from oncological treatments, and worst 48-month survival compared to other types.

ESC HEART FAILURE (2022)

Add to Collection

Article Hematology

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study

Isabelle Mahe, Giancarlo Agnelli, Cihan Ay, Aristotelis Bamias, Cecilia Becattini, Marc Carrier, Celine Chapelle, Alexander T. Cohen, Philippe Girard, Menno Huisman, Frederikus A. Klok, Juan J. Lopez-Nunez, Anthony Maraveyas, Didier Mayeur, Olivier Mir, Manuel Monreal, Marc Righini, Charles M. Samama, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Eric Vicaut, Tzu-Fei Wang, Guy Meyer, Silvy Laporte

Summary: The API-CAT study aims to evaluate whether a reduced-dose regimen of apixaban is noninferior to a full-dose regimen in preventing recurrent VTE in cancer patients. This international, randomized, double-blind trial will assess VTE events as the primary efficacy outcome and clinically relevant bleeding as the principal safety endpoint.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Oncology

Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study

Sabina Medrek, Sebastian Szmit

Summary: Lung cancer is a highly lethal disease, and its prognosis is influenced by histopathological and molecular diagnosis, clinical advancement, performance status, and comorbidities. Certain echocardiographic parameters are associated with poor performance status, providing objective confirmation of exercise intolerance in lung cancer patients. Atrial fibrillation and high heart rate in electrocardiogram are predictive of early death. Selected echocardiographic parameters can help predict poor prognosis in lung cancer patients and, when combined with electrocardiogram evaluation, broaden the possibilities of prognostic assessment.

CANCERS (2022)

Add to Collection

Article Environmental Sciences

Physical Activity in Pulmonary Arterial Hypertension during Pandemic COVID-19 and the Potential Impact of Mental Factors

Maria Wieteska-Milek, Sebastian Szmit, Michal Florczyk, Anna Witowicz, Marcin Kurzyna

Summary: This study analyzed the level of physical activity and the potential impact of mental factors on PAH patients during the COVID-19 pandemic. The findings showed that almost half of the patients had low physical activity, and mental factors did not significantly affect their physical activity.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

G. A. Lee, S. Aktaa, E. Baker, C. P. Gale, Israa F. Yaseen, G. Gulati, R. Asteggiano, S. Szmit, A. Cohen-Solal, A. Abdin, W. Jurczak, P. Garrido Lopez, A. L. Sverdlov, C. G. Tocchetti, A. Barac, I. Parrini, P. Zamorano, Z. Iakobishvili, R. Pudil, L. Badimon, A. M. Kirby, A. H. Blaes, D. Farmakis, G. Curigliano, R. Stephens, A. R. Lyon, T. Lopez-Fernandez

Summary: The aim of this study is to develop quality indicators (QIs) for evaluating the prevention and management of cancer therapy-related cardiovascular toxicity. The study followed the ESC methodology and involved identifying key domains of care, conducting a literature review, and selecting the final set of indicators. The study was conducted in collaboration with various associations and resulted in the selection of 5 main and 9 secondary QIs across five domains of care. Overall, this study is of great importance in improving clinical practice and patient outcomes.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Add to Collection

Article Oncology

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy

Magdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, Pawel Badurak, Katarzyna Zajda, Anna Janowicz-Zebrowska, Aleksandra Piorek, Magdalena Knetki-Wroblewska, Piotr Jaskiewicz, Adam Pluzanski, Maciej Krzakowski, Dariusz M. Kowalski

Summary: Concurrent platinum-based chemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is the most effective therapy in unresectable stage III non-small-cell lung cancer (NSCLC). However, severe toxicity may lead to unsatisfactory outcomes. Sequential CRT may be a better choice for patients with cardiovascular diseases (CVD) to avoid adverse events and maintain effectiveness. Beta-blockers and statins can significantly reduce all-cause mortality in these patients, and may serve as a prevention strategy in NSCLC patients undergoing CRT.

CANCERS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts - cardiologists and oncologists

Przemyslaw Leszek, Aneta Klotzka, Stanislaw Bartus, Pawel Burchardt, Anna M. Czarnecka, Monika Dlugosz-Danecka, Marek Gierlotka, Hanna Kosela-Paterczyk, Agata Krawczyk-Ozog, Tomasz Kubiatowski, Marcin Kurzyna, Adam Maciejczyk, Przemyslaw Mitkowski, Aleksander Prejbisz, Piotr Rutkowski, Ewa Sierko, Maciej Sterlinski, Sebastian Szmit, Marek Szwiec, Mateusz Tajstra, Agnieszka Tycinska, Adam Witkowski, Wojciech Wojakowski, Bozena Cybulska-Stopa, Jacek Mackiewicz, Ewa Straburzynska-Migaj

KARDIOLOGIA POLSKA (2023)

Add to Collection

Article Hematology

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

J. Goedegebuur, D. Abbel, S. Accassat, W. P. Achterberg, A. Akbari, V. M. Arfuch, E. Baddeley, J. J. Bax, D. Becker, B. Bergmeijer, L. Bertoletti, J. W. Blom, A. Calvetti, S. C. Cannegieter, L. Castro, N. Coma-Auli, N. H. Chavannes, C. Couffignal, A. Edwards, M. Edwards, H. Enggaard, C. Font, A. Gava, G. J. Geersing, E. C. T. Geijteman, S. Greenley, C. Gregory, J. Gussekloo, I. Hoffmannu, A. A. Hojen, W. B. van den Hout, M. V. Huisman, S. Jacobsen, J. Jagosh, M. J. Johnson, L. Jorgensen, C. C. M. Juffermans, E. K. Kempers, S. Konstantinides, A. F. Kroder, M. J. H. A. Kruip, L. Lafaie, J. W. Langendoen, T. B. Larsen, K. Lifford, Y. M. van der Linden, I. Mahe, L. Maiorana, A. Maraveyas, E. S. L. Martens, D. Mayeur, T. E. van Mens, K. Mohr, S. P. Mooijaart, F. E. M. Murtagh, A. Nelson, P. B. Nielsen, A. G. Ording, M. Orskov, M. Pearson, G. Poenou, J. E. A. Portielje, D. Raczkiewicz, K. Rasmussen, E. Trinks-Roerdink, I. Schippers, K. Seddon, K. Sexton, S. Sivell, F. Skjoth, M. Sogaard, S. Szmit, S. Trompet, P. Vassal, C. Visser, L. M. van Vliet, E. Wilson, F. A. Klok, S. I. R. Noble

Summary: The SERENITY consortium aims to develop an information-driven shared decision support tool for the appropriate use of antithrombotic therapy in people with cancer at the end of life. The use of this tool is expected to enhance empowerment and improve quality of life and treatment satisfaction for patients with advanced cancer and their caregivers.

THROMBOSIS RESEARCH (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Long COVID syndrome after SARS-CoV-2 survival in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Maria Wieteska-Milek, Beata Kusmierczyk-Droszcz, Katarzyna Betkier-Lipinska, Sebastian Szmit, Michal Florczyk, Piotr Zielinski, Piotr Hoffman, Pawel Krzesinki, Marcin Kurzyna

Summary: The study focuses on the impact of COVID-19 on pulmonary hypertension (PH) prognosis in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The findings show that over 60% of PAH/CTEPH patients who survived COVID-19 experienced long COVID-19 syndrome, but their 1-year risk of death due to PH did not significantly change. Common persistent symptoms reported by patients include fatigue, joint and muscle pain, nasal congestion, anosmia, insomnia, and dyspnea. The majority of patients had a low or intermediate-low risk of 1-year death due to PH both before and after COVID-19.

PULMONARY CIRCULATION (2023)

Add to Collection

Correction Cardiac & Cardiovascular Systems

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (vol 23, pg e333, 2022)

Alexander R. Lyon, Teresa Lopez-Fernandez, Liam S. Couch, Riccardo Asteggiano, Marianne C. Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan F. Dent, Dimitrios Farmakis, Sofie A. Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S. Salinger, Richard Stephens, Thomas M. Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2023)

Add to Collection

Article Pharmacology & Pharmacy

Savolitinib for non-small cell lung cancer

Magdalena Zaborowska-Szmit, Sebastian Szmit, Maciej Krzakowski, Dariusz M. Kowalski

Summary: Savolitinib is a highly selective MET tyrosine kinase inhibitor that can treat acquired resistance to TKI therapy in cancer patients with EGFR gene mutation. It is especially effective in NSCLC patients with MET exon 14 skipping mutation.

DRUGS OF TODAY (2023)

Add to Collection

Correction Cardiac & Cardiovascular Systems

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (vol 43, pg 4229, 2022)

Alexander R. Lyon, Teresa Lopez-Fernandez, Liam S. Couch, Riccardo Asteggiano, Marianne C. Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan F. Dent, Dimitrios Farmakis, Sofie A. Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S. Salinger, Richard Stephens, Thomas M. Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Oncology

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer

Marta Olszyna-Serementa, Magdalena Zaborowska-Szmit, Sebastian Szmit, Piotr Jaskiewicz, Katarzyna Zajda, Maciej Krzakowski, Dariusz M. M. Kowalski

Summary: This study aims to determine the usefulness of Karnofsky performance status (KPS) monitoring and to define the factors determining clinical deterioration during sequential chemoradiotherapy. The study included 196 patients and found that deterioration of KPS was associated with disease control rate 6 weeks after the end of chemoradiotherapy.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Hematology

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer

Anna Falanga, Avi Leader, Chiara Ambaglio, Zsuzsa Bagoly, Giancarlo Castaman, Ismail Elalamy, Ramon Lecumberri, Alexander Niessner, Ingrid Pabinger, Sebastian Szmit, Alice Trinchero, Hugo Ten Cate, Bianca Rocca

Summary: Thrombocytopenia is a common condition in cancer patients and can limit the use of antithrombotic treatments. Owing to the increased risk of bleeding and the potential interactions with anticancer medications, managing thrombocytopenia in cancer patients requires special attention. The European Hematology Association and the European Society of Cardiology have collaborated to provide clinical practice guidelines for the management of cancer patients with thrombocytopenia.

HEMASPHERE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

Alexander R. Lyon, Teresa Lopez-Fernandez, Liam S. Couch, Riccardo Asteggiano, Marianne C. Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan F. Dent, Dimitrios Farmakis, Sofie A. Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S. Salinger, Richard Stephens, Thomas M. Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal, Patrizio Lancellotti, Franck Thuny, Magdy Abdelhamid, Victor Aboyans, Berthe Aleman, Joachim Alexandre, Ana Barac, Michael A. Borger, Ruben Casado-Arroyo, Jennifer Cautela, Jolanta Celutkiene, Maja Cikes, Alain Cohen-Solal, Kreena Dhiman, Stephane Ederhy, Thor Edvardsen, Laurent Fauchier, Michael Fradley, Julia Grapsa, Sigrun Halvorsen, Michael Heuser, Marc Humbert, Tiny Jaarsma, Thomas Kahan, Aleksandra Konradi, Konstantinos C. Koskinas, Dipak Kotecha, Bonnie Ky, Ulf Landmesser, Basil S. Lewis, Ales Linhart, Gregory Y. H. Lip, Maja Lisa Lochen, Katarzyna Malaczynska-Rajpold, Marco Metra, Richard Mindham, Marie Moonen, Tomas G. Neilan, Jens Cosedis Nielsen, Anna Sonia Petronio, Eva Prescott, Amina Rakisheva, Joe Elie Salem, Gianluigi Savarese, Marta Sitges, Jurrien ten Berg, Rhian M. Touyz, Agnieszka Tycinska, Matthias Wilhelm, Jose Luis Zamorano, Nadia Laredj, Parounak Zelveian, Peter P. Rainer, Fuad Samadov, Uladzimir Andrushchuk, Bernhard L. Gerber, Mirsad Selimovic, Elena Kinova, Jure Samardzic, Evagoras Economides, Radek Pudil, Kirsten M. Nielsen, Tarek A. Kafafy, Riina Vettus, Suvi Tuohinen, Stephane Ederhy, Zurab Pagava, Tienush Rassaf, Alexandros Briasoulis, Daniel Czuriga, Karl K. Andersen, Yvonne Smyth, Zaza Iakobishvili, Iris Parrini, Amina Rakisheva, Edita Pllana Pruthi, Erkin Mirrakhimov, Oskars Kalejs, Hadi Skouri, Hisham Benlamin, Diana Zaliaduonyte, Alessandra Iovino, Alice M. Moore, Daniela Bursacovschi, Aatif Benyass, Olivier Manintveld, Marijan Bosevski, Geeta Gulati, Przemyslaw Leszek, Manuela Fiuza, Ruxandra Jurcut, Yury Vasyuk, Marina Foscoli, Dragan Simic, Miroslav Slanina, Luka Lipar, Ana Martin-Garcia, Laila Huebbert, Reto Kurmann, Ahmad Alayed, Leila Abid, Cafer Zorkun, Elena Nesukay, Charlotte Manisty, Nigora Srojidinova

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Review Medicine, General & Internal

Management of Anticoagulation in Cancer Patients with Atrial Fibrillation

Sebastian Szmit, Jaroslaw Kepski, Michal Wilk

Summary: Atrial fibrillation is a growing concern in cardio-oncology, with specific risk factors including cancer type and anticancer drugs. Anticoagulation therapy needs to be personalized based on the risk of detrimental interactions and bleeding.

ISRAEL MEDICAL ASSOCIATION JOURNAL (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.